IGHE and food allergy: Omalizumab (OMA), an anti-IgE monoclonal antibody (mAB), has been studied in individuals with IgE-mediated food allergy (FA) both as monotherapy and as an adjuvant to OIT (OMA+OIT) in order to address the need for a treatment that goes beyond allergen avoidance [50,51].